Focus on the target: The tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 2012

Journal for ImmunoTherapy of Cancer

Volumn 1, Issue , 2013, Pages

  Sunay, Melek Erdinc ^a   Marincola, Francesco ^b   Khleif, Samir N ^c   Silverstein, Samuel C ^d,e   Fox, Bernard A ^f   Galon, Jerome ^g   Emens, Leisha A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e College of Physicians and Surgeons ^*  (United States)

^f EARLE A CHILES RESEARCH INSTITUTE   (United States)

^g CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Cancer; Immunoscore; Immunotherapy; Suppressor cells; Tumor immunology; Tumor microenvironment

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; SUNITINIB; TADALAFIL; TRASTUZUMAB;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CD3+ T LYMPHOCYTE; CELLULAR IMMUNITY; DELAYED HYPERSENSITIVITY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; MEDICAL SOCIETY; METASTASIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR INVASION; TUMOR MICROENVIRONMENT; WORKSHOP;

EID: 84991030775     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/2051-1426-1-9     Document Type: Article

References (50)

1. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH: Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010, 8:1093-1102.
2. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-1310.
3. Schumacher K, Haensch W, Roefzaad C, Schlag PM, Schumacher K, Haensch W, Roefzaad C, Schlag PM: Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001, 61:3932-3936.
4. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.
5. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, et al: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998, 58:3491-3494.
6. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O'Brien-Jenkins A, Gimotty PA, Coukos G: Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008, 14:28-36.
7. Mellor AL, Munn DH: Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 2008, 8:74-80.
8. Spiotto MT, Schreiber H: Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immunology 2005, 5:8-12.
9. Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Scheitinger A, Yu P, Fu YX, Weischelbaum RR, Rowley DA, Kranz DM, Schreiber H: Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 2007, 204:49-55.
10. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH: Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2, 3-dioxygenase. J Clin Invest 2007, 117:2570-2582.
11. Munn DH: Blocking IDO activity to enhance anti-tumor immunity. Front Biosci 2012, 4:734-745.
12. Munn DH: GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity 2005, 22:633-642.
13. Munn DH, Mellor AL: Indoleamine 2, 3 dioxygenase and metabolic control of immune responses. Trends Immunol 2013, 34(3):137-143. doi:10.1016/j. it.2012.10.001. Epub 2012 Oct 25.
14. Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, Ochando JC, Cabrelle A, Mandruzzato S, Bronte V: Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep 2012, 2:628-639.
15. Gajewski TF, Louahed J, Brichard VG: Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 2010, 16:399-403.
16. + dendritic cells. J Exp Med 2011, 208:2005-2016.
17. Zheng Y, Zha Y, Driessens G, Locke F, Gajewski TF: Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med 2012, 209:2157-2163.
18. Cipponi A, Mercier M, Seremet T, Baurain JF, Theate I, van den Oord J, Stas M, Boon T, Coulie PG, Van Baren N: Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res 2012, 72:4997-5002.
19. Budhu S, Loike JD, Pandolfi A, Han S, Catalano G, Constantinescu A, Clynes R, Silverstein SC: CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med 2010, 207:223-235.
20. Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, Huls H, Miller JC, Kebriaei P, Rabinovitch B, Lee DA, Champlin RE, Bonini C, Naldini L, Rebar EJ, Gregory PD, Holmes MC, Cooper LJ: A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 2012, 119:5697-5705.
21. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al: Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
22. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al: Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012, 4:127-ra137.
23. Pardoll DM: Immunology beats cancer: a blueprint for successful translation. Nat Immunol 2012, 13:1129-1132.
24. Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, Khleif SN: Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 2011, 41:2977-2986.
25. Mkrtichyan M, Najjar YG, Raulfs EC, Liu L, Langerman S, Guittard G, Ozbun L, Khleif SN: B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. J Immunol 2012, 189:2338-2347.
26. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A: CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 2011, 17:4101-4109.
27. Bellovin DI, Das B, Felsher DW: Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs. Adv Exp Med Biol 2013, 734:91-107.
28. Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, Fan AC, Yang Q, Braunstein L, Crosby E, Ryeom S, Felsher DW: CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010, 18:485-498.
29. Deguine J, Bousso P: Dynamics of NK cell interactions in vivo. Immunol Rev 2013, 251:154-159.
30. Deguine J, Breart B, Lemaître F, Bousso P: Cutting edge: tumor-targeting antibodies enhance NKG2D-mediated NK cell cytotoxicity by stabilizing NK cell-tumor cell interactions. J Immunol 2012, 189:5493-5497.
31. Crespo J, Sun H, Welling TH, Tian Z, Zou W: T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol 2013, S0952-7915:00193-00198.
32. Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, Palmer DC, Reger RN, Borman ZA, Zhang L, Morgan RA, Gattinoni L, Rosenberg SA, Trinchieri G, Restifo NP: Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 2010, 70:6725-6734.
33. Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, Leonardi AJ, Morgan RA, Wang E, Marincola FM, Trinchieri G, Rosenberg SA, Restifo NP: IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011, 121:4746-4757.
34. Jinushi M, Nakazaki Y, Dougan M, Carrasco DR, Mihm M, Dranoff G: MFG-E8-mediated uptake of apoptotic cells by APCs links the pro-and antiinflammatory activities of GM-CSF. J Clin Invest 2007, 117:1902-1913.
35. Jinushi M, Sato M, Kanamoto A, Itoh A, Nagai S, Koyasu S, Dranoff G, Tahara H: Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomouse and immune-mediated mechanisms. J Exp Med 2009, 206:1317-1326.
36. Ali OA, Emerich D, Dranoff G, Mooney DJ: In situ regulation of CD subsets and T cells mediates tumor regression in mice. Sci Transl Med 2009, 1:8-ra19.
37. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002, 20:2624-2632.
38. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, Dela Rosa C, Tietje K, Link J, Waisman J, Salazar LG: Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009, 27:4685-4692.
39. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Rinke JH: Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009, 15:2148-2153.
40. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, et al: Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012, 18:1254-1261.
41. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I: Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. Journal Exp Med 2006, 203:2691-2702.
42. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, Jaffee EM: Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocytemacrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009, 27:5911-5918.
43. Zlobec I, Baker K, Terracciano L, Peter S, Degen L, Beglinger C, Lugli A: Two-marker protein profile predicts poor prognosis in patients with early rectal cancer. Br J Cancer 2008, 99:1712-1717.
44. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654-2666.
45. Zlobec I, Minoo P, Baumhoer D, Baker K, Terracciano L, Jass JR, Lugli A: Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer 2008, 112:495-502.
46. Fridman WH, Pages F, Sautes-Fridman C, Galon J: The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012, 12:298-306.
47. Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA: The immunoscore as a new possible approach for the classification of cancer. J Transl Med 2012, 3:10-11.
48. Galon J, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, et al: Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012, 1:205.
49. Ugurel S, Schrama D, Keller G, Schadendorf D, Brocker EB, Houben R, Zapatka M, Fink W, Kaufman HL, Becker JC: Impact of CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother 2008, 57:685-691.
50. Wang E, Uccellini L, Marincola FM: A genetic inference on cancer immune responsiveness. Oncoimmunology 2012, 1:520-525.